← Back to Screener
Revolution Medicines, Inc. Common Stock (RVMD)
Price$163.68
Value ScoreF
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)109.43%
Price vs S&P 500 (4W)7.93%
VGM Score46.66
Market Capitalization$33.48B
All Metrics
Book Value / Share (Quarterly)$7.49
P/TBV (Annual)9.77x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-5.35
Price vs S&P 500 (YTD)86.78%
Net Profit Margin (TTM)-2833.88%
EPS (TTM)$-4.80
10-Day Avg Trading Volume2.76M
EPS Excl Extra (TTM)$-4.80
EPS (Annual)$-5.95
ROI (Annual)-59.55%
Net Profit Margin (5Y Avg)-1090.94%
Cash / Share (Quarterly)$9.53
ROA (Last FY)-48.05%
EBITD / Share (TTM)$-4.90
ROE (5Y Avg)-37.42%
Operating Margin (TTM)-3145.03%
Cash Flow / Share (Annual)$-4.64
P/B Ratio22.32x
P/B Ratio (Quarterly)12.85x
Net Income / Employee (Annual)$-1,281,200
EV / Revenue (TTM)2879.31x
ROA (TTM)-39.14%
EPS Incl Extra (Annual)$-5.95
Current Ratio (Annual)7.14x
Quick Ratio (Quarterly)6.59x
3-Month Avg Trading Volume2.88M
52-Week Price Return302.92%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$7.21
P/S Ratio (Annual)2891.16x
Asset Turnover (Annual)0.01x
52-Week High$158.13
Operating Margin (5Y Avg)-1188.51%
EPS Excl Extra (Annual)$-5.95
CapEx CAGR (5Y)40.41%
Tangible BV CAGR (5Y)30.65%
26-Week Price Return125.36%
Quick Ratio (Annual)6.97x
13-Week Price Return54.17%
Total Debt / Equity (Annual)0.16x
Current Ratio (Quarterly)6.80x
Enterprise Value$33.32B
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)3.04%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-3798.71%
Cash / Share (Annual)$10.28
3-Month Return Std Dev92.49%
Net Income / Employee (TTM)$-1,039,500
ROE (Last FY)-69.35%
EPS Basic Excl Extra (Annual)$-5.95
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.19x
EPS Incl Extra (TTM)$-4.80
Receivables Turnover (Annual)0.00x
ROI (TTM)-46.96%
P/S Ratio (TTM)2893.16x
Pretax Margin (5Y Avg)-1099.19%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$8.00
Price vs S&P 500 (52W)274.71%
Year-to-Date Return97.72%
5-Day Price Return3.91%
EPS Normalized (Annual)$-5.95
ROA (5Y Avg)-29.73%
Net Profit Margin (Annual)-3768.28%
Month-to-Date Return9.27%
Cash Flow / Share (TTM)$-3.25
EBITD / Share (Annual)$-6.18
Operating Margin (Annual)-4207.12%
LT Debt / Equity (Annual)0.16x
ROI (5Y Avg)-35.46%
LT Debt / Equity (Quarterly)0.19x
EPS Basic Excl Extra (TTM)$-4.80
P/TBV (Quarterly)13.35x
P/B Ratio (Annual)9.44x
Pretax Margin (TTM)-2830.92%
Book Value / Share (Annual)$8.28
Price vs S&P 500 (13W)44.42%
Beta1.41x
Revenue / Share (TTM)$0.00
ROE (TTM)-54.06%
52-Week Low$34.00
vGradeF
mGradeA
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-2.29est. -1.88
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.37
4.37
4.37
4.37
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
| TECHBio-Techne Corp. | D | C | C | $50.79 |
About
Revolution Medicines is a clinical-stage precision oncology company developing targeted therapies for RAS-addicted cancers. The company leverages proprietary structure-based drug discovery capabilities to create small molecules that bind to unconventional RAS variant sites. Its pipeline centers on RAS(ON) Inhibitors designed for use as monotherapy or in combination with other therapeutic agents.